Semaglutide May Improve Motivation in Patients with Major Depressive Disorder

Treatment with semaglutide has shown significant improvements in measures of motivation for individuals diagnosed with major depressive disorder (MDD), according to a recent study published in JAMA Psychiatry. The research was conducted by Hartej Gill, Ph.D., from the University of Toronto, and his team. In their analysis, 72 participants with MDD and a body mass index (BMI) ≥25 kg/m² were randomly assigned either semaglutide or a placebo for treatment.

The study aimed to assess how semaglutide affects reward-related dysfunction in patients with MDD. The researchers observed that semaglutide-treated participants exhibited an increased willingness to exert physical efforts, particularly when the expected value of rewards was higher (treatment × visit × expected value interaction: Χ² = 12.024). This effect on choice behavior was attributed to reduced effort discounting, as evidenced by computational modeling.

The study also found that semaglutide led to a significant reduction in sensitivity (\( \beta = -1.737 \)), while there was no treatment effect observed on the sensitivity to probability (\( \beta = -0.776 \)). The authors of the study noted, "Semaglutide reduced the perceived cost of effort relative to the monetary reward; these results have implications for treating multiple neuropsychiatric disorders characterized by varied reward dysfunctions."

Two of the researchers disclosed ties to the pharmaceutical industry. This study adds to growing evidence that semaglutide may offer therapeutic benefits beyond its established role in managing type 2 diabetes.

Semaglutide, a medication originally developed as an incretin mimetic for treating type 2 diabetes, has shown promise in various neurological and psychiatric conditions due to its ability to modulate reward pathways. The findings of this study suggest that semaglutide could potentially be repurposed or combined with other treatments to improve motivation in individuals suffering from MDD.

While the results are promising, further research is needed to confirm these effects and explore potential side effects. Nonetheless, the study highlights the versatility of semaglutide as a treatment option for patients with major depressive disorder who may benefit from enhanced motivational responses.